Stockreport

Amylyx Pharmaceuticals (AMLX) Winds Up Avexitide Phase 3 Lucidity Trial Enrollment [Yahoo! Finance]

Amylyx Pharmaceuticals, Inc.  (AMLX) 
PDF On March 24, Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) stated that the final subject in the Phase 3 Lucidity clinical study of avexitide had been randomised and dosed. [Read more]